Codexis Stock Rating Upgraded by Wall Street Zen

Analysts change rating on biotech company's shares from 'strong sell' to 'hold'

Mar. 16, 2026 at 5:08am

Got story updates? Submit your updates here. ›

Codexis, a protein engineering company based in Redwood City, California, has had its stock rating upgraded by Wall Street Zen from a 'strong sell' to a 'hold' rating. The upgrade comes after the company reported earnings results on March 11th that beat analyst estimates.

Why it matters

Codexis is a leading biotech company focused on developing innovative enzyme solutions for various industries. The stock rating upgrade from a prominent research firm signals a potential shift in investor sentiment around the company's future prospects.

The details

In addition to the upgrade from Wall Street Zen, other analysts have also weighed in on Codexis recently. Cantor Fitzgerald reissued an 'overweight' rating on the shares, while Weiss Ratings restated a 'sell (e+)' rating. Stifel Nicolaus set a $5.00 target price on the stock. Overall, the consensus rating is now 'Hold' with a $5.00 target price.

  • Codexis reported earnings on March 11, 2026.
  • Wall Street Zen upgraded the stock rating on March 16, 2026.

The players

Codexis

A leading protein engineering company focused on developing innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications.

Wall Street Zen

An equity research firm that upgraded Codexis' stock rating from 'strong sell' to 'hold'.

Cantor Fitzgerald

An investment bank that reissued an 'overweight' rating on Codexis shares.

Weiss Ratings

A research firm that restated a 'sell (e+)' rating on Codexis stock.

Stifel Nicolaus

An investment bank that set a $5.00 target price on Codexis.

Got photos? Submit your photos here. ›

The takeaway

The rating upgrade from Wall Street Zen suggests a potential shift in investor sentiment around Codexis' future prospects, though the overall consensus remains neutral with a 'Hold' rating. The company's ability to continue delivering strong financial results and innovative enzyme solutions will be key to driving further stock price appreciation.